Ampiroxicam (INN) is a non-steroidal anti-inflammatory drug (NSAID). It is a prodrug of piroxicam.[1] It has been studied for potential anticancer activity, but preliminary results did not show evidence of such activity.[2][3]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.235.757 |
Chemical and physical data | |
Formula | C20H21N3O7S |
Molar mass | 447.46 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
References edit
- ^ Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, Weissman A (July 1993). "Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam". Agents Actions. 39 (3–4): 157–65. doi:10.1007/BF01998969. PMID 8304243. S2CID 24284281.
- ^ Choi, K.-H.; Shim, J.-H.; Huong, L. D.; Cho, N.-P.; Cho, S.-D. (July 2011). "Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma". Oral Diseases. 17 (5): 469–475. doi:10.1111/j.1601-0825.2010.01774.x. ISSN 1601-0825. PMID 21496182.
- ^ Shim, Jung-Hyun; Shin, Ji-Ae; Jung, Ji-Youn; Choi, Kyeong-Hee; Choi, Eun-Sun; Cho, Nam-Pyo; Kong, Gu; Ryu, Mi Heon; Chae, Jung-Ii; Cho, Sung-Dae (March 2011). "Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1". European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). 20 (2): 102–111. doi:10.1097/CEJ.0b013e328341e38f. ISSN 1473-5709. PMID 21131823.